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ABSTRACT
Objective: This study was aimed to obtain a new excipient that can be used as a polymer matrix for the formulation of controlled release dosage forms.
Methods: This study used coprocessing and crosslinking methods on amylose and xanthan gum (XG) to obtain a new excipient that can be used 
for controlled release matrix of pharmaceutical dosage forms. The coprocessing step was conducted by drum drying, and the crosslinking step was 
prepared using 6 and 12% sodium trimetaphosphate (STMP). The produced novel excipients were characterized in terms of infrared (IR) spectrum, 
substitution degree, moisture content, swelling index, and gel strength.
Results: Our results showed that amylose–XG excipients crosslinked using 6% STMP have greater gel strength and better swelling indexes than 
excipients crosslinked using 12% STMP. All coprocessed excipients exhibited no differences in their IR spectra, whereas the crosslinked excipients 
did, indicating a structural change due to the addition of phosphate groups. Crosslinking amylose–xanthan-coprocessed excipients using 6% STMP 
produced degrees of substitution (DSs) of 7–8 phosphates per 100 monomeric subunits. The excipients had a moisture content of 8.21–12.85%, and 
the pH of a 1% solution of excipients was 6.21–6.43. In addition, the swelling index and gel strength of the excipient where both amylose and XG were 
crosslinked together Were more than 1 where only amylose was crosslinked.
Conclusion: The crosslinking amylose–xanthan-coprocessed excipient using 6% STMP is more suitable for use in controlled release dosage forms, 
particularly when the polymer ratio is 1:1.
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INTRODUCTION
Polysaccharides such as pectin, chitosan, starch, guar gum, and xanthan 
are commonly used in controlled release dosage forms of various 
pharmaceuticals due to their low cost, biocompatibility, low toxicity, 
ease of chemical modification, and biodegradability [1-4]. Among the 
various types of commercially available starch, high-amylose starch 
has been demonstrated to possess superior properties with regard to 
drug delivery compared with native starch [5]. Xanthan gum (XG) has 
also been studied as an ingredient for producing a direct compression 
matrix with high swelling properties [6,7].
Polymer modification can improve the physical and functional properties 
of each constituent polymer. Crosslinking has been proven to improve 
various characteristics of excipients such as swelling properties, 
solubility at various pHs, gel strength, mucoadhesive properties, and 
resistance to enzymatic modification or degradation. Many studies 
have demonstrated the successful application of high-amylose starch 
crosslinked using different agents, such as epichlorohydrin and 
sodium trimetaphosphate (STMP), in the development of controlled 
drug delivery systems [5,8,9]. Lenaerts et al. have demonstrated that 
crosslinked amylose (CLA) can be used in controlled drug release 
systems over periods of 18–24 h [10]. CLA with degrees of substitution 
(DSs) of 6–8 exhibits a good release profile when used as matrix in 
controlled-release tablets (15–20 h); in contrast, high DS (>10) results 
in a significant decrease in the drug release time profile (1–3 h), 
indicating that substitution can cause it to act as a disintegrants [11]. 
Meanwhile, according to Bejenariu et al., crosslinking using STMP 
increases the gel strength of XG, which can then be used in controlled 
drug release systems [12].
Coprocessing is a new concept of manipulating the physical interaction 
of two or more excipients at the particulate level. The advantage of this 
method is that it can improve flow properties and compressibility and 
reduce weight variations by producing a single excipient with multiple 
functions. This can minimize the use of multiple excipients, produce 
excipients with improved functional properties with respect to viscosity 
or gel strength, and overcome the undesirable properties of the 
individual excipients to produce strong tablets with low compression 
pressure [13-15].
Based on these ideas, in this study, we modified high-amylose starch and 
XG using two methods. In the first, high-amylose starch was crosslinked 
using STMP and then coprocessed (Co) with XG. In the second, amylose 
and XG were coprocessed and then crosslinked using STPM to produce 
Co CLA–XG.
Coprocessed excipients consisting of XG and CLA were used as in 
the preparation of a sustained release matrix. Sustained release 
dosage forms have the advantages of reducing the frequency of drug 
administration, increasing patient compliance, minimizing drug level 
fluctuations in plasma, producing constant pharmacological effects 
(especially for drugs with short biological half-lives), and reducing the 
drug’s side effects.
Sodium diclofenac is a nonsteroidal anti-inflammatory drug that 
is often used to treat a variety of pain, such as that due to migraines 
and osteoarthritis. This drug has a short half-life of 1–2 h and oral 
bioavailability of approximately 50% due to the first-pass metabolism 
in the liver. Frequent dosing is used for long-term treatment for 
osteoarthritis. For these reasons, sodium diclofenac was chosen as a 
model drug in this study as a slow release of the drug would be expected 
Research Article
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ijap.2018.v10s1.13
The 2nd Physics and Technologies in Medicine and Dentistry Symposium (PTMDS), Universitas Indonesia. Depok, Indonesia
 The 2nd Physics and Technologies in Medicine and Dentistry Symposium (PTMDS), Universitas Indonesia. Depok, Indonesia 60
Int J App Pharm, Vol 10, Special Issue 1, 2018
 Surini et al. 




Sodium diclofenac (Kimia Farma, Indonesia); high-amylose starch 
(Shangqiu Kangmedia Bio-Tech, China); XG (CV. Tristars Chemicals, 
Indonesia); STMP (Shangqiu Kangmedia Bio-Tech, China); sodium 
hydroxide (Merck, Jerman); chloride acid (Merck, Jerman); 96% 
ethanol (Brataco, Indonesia); and distilled water (Brataco, Indonesia) 
were used.
Methods
Synthesis of  Co CLA-XG and CL Co-A-XG
Two methods, which were modified from the method of Cury et al. [16], 
were used. In the first, amylose was first crosslinked and then 
coprocessed with XG to produce Co CLA-XG. Amylose was crosslinked 
using STMP after adjusting the pH to 11–12 by adding 4% NaOH. STMP 
was used at concentrations of 6% or 12%, and the reaction time was 
1–4 h. Once the reaction was completed, the amylose suspension was 
neutralized using HCl to pH±6 and then washed with 96% ethanol. The 
CLA was then air-dried and sieved using a 35-mesh sieve. CLA and XG 
were then dispersed in distilled water, homogenized for 15 min, and 
then dried in a drum drier at 80°C±5°C. The powder was then milled 
and sieved through a 35-mesh sieve. Three combinations of CLA and XG 
were produced at 1:1, 1:2, and 2:1.
In the second method, amylose and XG were first  coprocessed and then 
crosslinked to produce CL Co-A-XG. A dispersion of amylose and XG in 
distilled water was homogenized for 15 min and then dried using drum 
drier at 80°C±5°C. The powder was then milled and sieved through a 
35-mesh sieve. Three combinations of amylose and XG were produced 
at 1:1, 1:2, and 2:1. This material was suspended in distilled water, and 
the pH was adjusted to 11–12 with 4% NaOH. STMP was added at a 
concentration of 6% or 12% and reacted for 1–4 h. Once the reaction 
was completed, the suspension was neutralized using HCl to pH±6 and 
then washed with 96% ethanol. The final material was then air-dried 
and sieved using a 35-mesh sieve.
Characterization of Co CLA-XG and CL Co-A-XG
Physical characterization
Physical characterization of Co CLA-XG and CL Co-A-XG included its 
morphology, thermal properties, powder flowability, moisture content, 
hygroscopicity, and solubility. The shape and morphology of the 
powders were assessed using a scanning electron microscope. Thermal 
analysis was conducted using thermogravimetry-differential thermal 
analysis. Crystallinity was measured by X-ray diffraction. Moisture 
content was measured with a moisture balance using 1 g of sample 
powder, which was then heated to 105°C. Hygroscopicity testing was 
conducted on a 1-g sample placed in a desiccator at room temperature 
and a humidity of 70% relative humidity. The sample was divided 
into four different containers and changes in weight before and after 
treatment were recorded.
Chemical characterization
Chemical characterization of Co CLA-XG and CL Co-A-XG was 
conducted with respect to pH, number of functional groups, and 
degree of crosslinking. The excipient was dissolved in distilled water 
at a concentration of 10% and pH was measured using a pH meter. 
Substitution of phosphate groups in starch was ascertained using 
infrared (IR) spectrophotometer. IR spectra of Co CLA-XG and CL Co-
A-XG were compared with those of amylose and XG. Phosphate groups 
exhibited specific absorption by ester bonds at wave numbers 1298.14 
and 2362.88 cm−1. The DS was measured using colorimetry.
Functional characterization
Functional characterization of Co CLA-XG and CL Co-A-XG powders was 
conducted on their flow properties, whereas viscosity and rheology, 
swelling index, and gel strength were assessed on their solutions/gels. 
The flow properties were measured with respect to flow rate, angle of 
repose, Hausner ratio, and compressibility index. Viscosity and rheology 
of Co CLA-XG and CL Co-A-XG were determined using their solutions 
at concentrations of 3%, 5%, 7%, and 10% w/v using a Brookfield 
viscometer. Swelling index was determined by comparing the weight 
of a dry tablet of excipient and the weight after it had been placed in 
10 mL of the medium of various pHs. Gel strength was measured using 
a texture analyzer on a solid gel of 10% Co CLA-XG or CL Co-A-XG that 
has been cooled to ±4°C for 2 h.
RESULTS AND DISCUSSION
Synthesis of Co CLA-XG and CL Co-A-XG
Crosslinking was achieved by reacting a 3% mucilago of each polymer 
in distilled water with 6% of STMP. The pH was adjusted to 11–12 by 
continuous addition of 10 N NaOH solution. The hydroxyl groups of 
amylose and XG were ionized under alkaline conditions and could react 
with the phosphate groups.
The reaction was conducted while stirring at 3000 rpm in a 
homogenizer, and the crosslinking reaction is considered complete if 
there is no longer any change in the pH of the solution. The solution was 
then neutralized by adding HCl till a pH of 6.5–7 is reached.
A 50% ethanol solution was added to the neutralized suspension to 
form a white precipitate. The precipitate was then washed with 50% 
ethanol until no phosphate was detected in the final rinse (identified by 
an absorption peak at 820 nm). The precipitate was dried using a drum 
drier at a temperature of 80±5°C, milled using a disc mill, and sieved 
through a 60-mesh sieve to obtain Co CLA-XG or CL Co-A-XG.
Characterization of Co CLA-XG
Physical properties
CLA consisted of fine, white granules, whereas Co CLA-XG consisted 
of non-porous yellowish white fine flakes/fibers. The flake/fiber 
morphology of Co CLA-XG was due to the drying process with a double 
drum drier that broke the starch granules and turned them into 
irregular thin flakes (Fig. 1).
Fig. 2: Particle-size distribution of Co CLA-XG powders
Fig. 1: Morphology of Co CLA-XG at ×200 (a) and ×10,000 
magnifications (b)
a b
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The most common particle size of the various excipient powders was 
356–500 µm, as shown in Fig. 2.
Table 1 shows that the moisture content of CLA was higher than that 
of Co CLA-XG. This was due to differences in drying methods; Co CLA-
XG was dried using a drum drier at a higher temperature than CLA, 
which was dried at room temperature. Nevertheless, all excipients 
contained <15% water and flowed well (Table 2), so they could be used 
as excipients in pharmaceutical dosage forms.
Morphology, particle size, and moisture content contribute to the flow 
properties of powder excipients. Table 2 shows that all versions of Co 
CLA-XG performed well. High water levels can also cause poor flow rates 
due to adhesion between particles to form larger particles. However, 
while CLA6 had a higher water content, its spherical granules resulted 
in a good flow rate.
Chemical properties
Amylose was first crosslinked using STMP at two different concentrations 
(6% and 12%) before Co with XG. Crosslinking produced CLA with 
different DSs: 0.07 and 0.11 (Table 3). This means that there are 
approximately 7 or 11 phosphate groups for every 100 anhydroglucose 
units in amylose depending on the STMP concentration. Crosslinking is 
expected to occur at C positions 2, 3, and 6 of the starch, with a higher 
probability at the C2 position because it has the highest reactivity [17].
pH measurement on 1% solutions of the various Co CLA-XGs showed 
that they had a pH close to neutral (Table 4). This shows that there 
was no/very little residual phosphate in this crosslinked excipient and 
indicates that it is safe to use since its pH is close to physiological pH.
Analysis of the functional groups of CL6 was performed using FTIR. 
This showed a specific absorption for P (O) O at 1298.14 cm−1, a peak 
for oxygen single bonds (–PO) of the phosphate group at 933.58 cm−1, 
and an oxygen double bond (−P = O) at 1062.81 cm−1. Amylose and 
CLA6 produced different spectra between 4000 and 2000 cm−1. The 
additional peak at 2362.88 cm−1 in CLA6 that was due to the phosphate 
groups from STMP has reacted with amylose, while the loss of the peak 
at 2945.40 cm−1 in CLA6 was due to the partial loss of hydroxyl groups 
through reaction with STMP.
Analysis of the functional groups of the Co-CLA6-XG was performed to 
identify the physical interactions between XG and CLA6. The absence 
of a new group that emerged proving that there were no chemical 
interactions.
Functional properties
Co CLA6-XG exhibited greater gel strength than Co CLA12-XG, suggesting 
that Co-CLA6 PVA might be more suitable as a controlled release matrix 
(Fig. 3).
Swelling index measurements were performed in distilled water and 
phosphate buffer at pH 7.4. Co CLA-XG exhibited greater swelling in 
water than in buffer. All Co CLA-XG variants swelled to 2 times their 
original volume in the first 90 min, suggesting that the Co excipients 
could potentially be used as slow-release dosage forms. Co CLA6-XG 
1:1 was the most promising excipient for use as a matrix with the 
ability to better retain and then release drugs. Results can be seen 
in Fig. 4.
Low viscosity is an indicator of a low gel strength, which can influence 
drug release. Co CLA-XG dispersed in distilled water exhibited 
pseudoplastic thixotropic flow properties, meaning that the viscosity 
of the solution decreased as the shear rate increased; however, when 
share rate is low, the viscosity of the solution does not immediately 
return to normal (Fig. 5).
Characterization of CL Co-A-XG
Physical properties
All Co-A-XG formulations were yellowish white flakes/fibers caused 
using a drum drier. In contrast, Co CLA-XG was non-porous, yellowish 
white, and granule-shaped. Differences in the shape of these modified 
excipients could impact their functional properties, such as flow rate 
and density. Morphology of CL Co-A-XG can be seen in Fig. 6.
Most of the powder particles were in the size range of 356–500 µm, as 
shown in Fig. 7.
Moisture content of Co A-XG was higher than that of CL Co-A-XG due to 
the different drying processes (Table 5). Co-A-XG was dried using the 
drum drying method; thus, its water content was lower than that of CL 
Co-A-XG, which was dried at room temperature.
Shape, size, and water content of the excipients impact the flow rate 
of the powder. Powder flow properties of all powders were in the fine 
category and their flow rates were quite good (Table 6).
Chemical properties
Crosslinking of Co-A-XG using STMP at concentrations of 6% and 12% 
resulted DSs listed in Table 7. Crosslinking of Co-A-XG with 6% STMP 
produced CL Co-A-XG with a DS of 0.08 while crosslinking using 12% 
STMP produced a DS of 0.11–0.12.
All the CL Co A-XG excipients at 1% concentration exhibited pHs close 
to neutrality (Table 8); however, all CL Co A-XG excipients had slightly 
Table 1: Moisture content of Co CLA-XG





Table 2: Flow properties of Co CLA-XG
Excipient Flow rate (g/det) Tapped density (g/ml) Compressibility index (%) Hausner ratio
CLA6:XG (1:1) 4.08 0.89 25.00 1.33
CLA6:XG (1:2) 4.05 0.87 24.59 1.33
CLA6:XG (2:1) 3.97 0.87 23.33 1.30
CLA12:XG (1:1) 4.17 0.89 25.00 1.33
CLA12:XG (1:2) 4.00 0.89 25.00 1.33
CLA12:XG (2:1) 4.14 0.89 25.00 1.33
Fig. 3: Gel strength of Co CLA-XG
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Fig. 5: Viscosity of Co CLA-XG
Table 3: Degree of substitution of crosslinked amylose
Excipient % p DS
CLA6 1.43±0.175 0.07±0.010
CLA12 2.12±0.418 0.11±0.025








Table 5: Moisture content of excipient




Co CLA-XG (1:1) 12.65±0.41
Co CLA-XG (1:2) 12.85±0.46
Co CLA-XG (2:1) 12.83±0.69
Fig. 4: Swelling indices of Co CLA-XG in (a) distilled water and (b) phosphate buffer at pH 7.4
a
b
Fig. 6: Morphology of CL Co-A-XG at 100× (a) and 5000× 
magnifications (b)
a b
higher pHs than their non-crosslinked counterparts. Nevertheless, all 
the excipients produced were considered to be compatible for use in 
formulations because they were close to the physiological pH of the 
body.
There was a difference in the IR spectra of Co A-XG and CL Co A-XG, 
indicating that crosslinking had altered the chemical structure of the 
excipient.
Chemical properties
CL Co A-XG showed more swelling in the buffer than in distilled water 
(Fig. 8) and expanded up to 800% in the buffer (10 times higher than 
that in distilled water).
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Fig. 7: Particle size distribution of coprocessed amylose-xanthan gum (Co-A-XG) (above) and CL Co-A-XG (below)
Fig. 8: Swelling index of CL Co-A-XG
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CLCoAXG 6 (1:1) 6.39±0.05
CLCoAXG 6 (1:2) 6.39±0.03
CLCoAXG 6 (2:1) 6.41±0.03
CLCoAXG 12 (1:1) 6.38±0.03
CLCoAXG 12 (1:2) 6.43±0.03
CLCoAXG 12 (2:1) 6.43±0.03
produced and tested, CL6 Co-A-XG (1:1) is the most suitable excipient 
for this purpose.
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